Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KUNLUN: durvalumab plus definitive chemoradiotherapy for unresectable esophageal squamous cell carcinoma
2023-506413-22-00Phase 3Authorised
- Sponsor
- AstraZeneca
- Start
- Mar 2021
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 16
01
Overview
Phase 3, randomised, double-blind trial in Esophageal Squamous Cell Carcinoma (ESCC) comparing Durvalumab + definitive chemoradiotherapy with Placebo + definitive chemoradiotherapy (2 arms). Primary endpoint: Progression-free survival in PD-L1 TAP>=1% tumors. Planned start Mar 2021; status: authorised.
02
Drugs
durvalumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on 2023-506413-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506413-22-00.